Company intelligence / Profile preview
Celladon Corporation
San Diego, California, United Statescelladon.net ↗
- Ownership
- Private
- Employees
- ~17
- Development stage
- Phase 2
01
Overview
Mydicar failed in Phase 2b trials in April 2015, missing all endpoints. The company subsequently suspended all R&D activities in June 2015.
- Therapeutic areas
- Metabolic DisordersCardiovascularEndocrinology
- Modalities
- Gene therapyEnzyme replacement therapySmall molecules
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Laboratories Servier (option agreement for SERCA2b modulators for diabetes)
Beyond the preview
Go deeper on Celladon Corporation.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Celladon Corporation.